Key Points
Oct 30 (Reuters) - Bluebird bio (BLUE.O) said on Monday it has agreed to sell its priority review voucher for $103 million if it gets the U.S. Food and Drug Administration's approval for its gene therapy to treat sickle cell disease...
The voucher, which is transferable, allows a drug developer to expedite the review process of its product even if it does not fit requirements for a quick process...
The FDA's advisers are scheduled to meet on Tuesday to decide on the sickle cell disease gene therapy jointly developed by Vertex Pharmaceuticals (VRTX.O) and Crispr Therapeutics (CRSP.BN)..
You might be interested in
New cure for sickle cell disease coming soon
31, Oct, 23US food advisors will look at a gene therapy that could tackle the root cause of the sickle cell disease.
US approves CRISPR gene-editing to treat sickle cell disease
10, Dec, 23The treatment for sickle cell disease uses the revolutionary gene-editing tool CRISPR to permanently change DNA in the patient's blood cells. | Health
Cure for sickle cell disease on the horizon? US drug regulator is reviewing 2 new gene therapies
03, Nov, 23FDA is scheduled to review gene therapies from two American companies — Vertex Pharmaceuticals & Bluebird Bio Inc. If approved, therapies could mean a breakthrough for curing SCD.
Bluebird bio submits US marketing application for blood disorder gene therapy
25, Apr, 23Bluebird bio Inc said on Monday it has submitted a marketing application to the U.S. Food and Drug Administration for its gene therapy to treat sickle cell disease.
US approves two gene therapies for sickle cell disease
08, Dec, 23The U.S. Food and Drug Administration (FDA) on Friday approved a pair of gene therapies for sickle cell disease, including the first treatment based on the breakthrough CRISPR gene editing technology.
US FDA advisers to consider need for more studies for Vertex/CRISPR gene therapy
27, Oct, 23A Gene Therapy Cure for Sickle Cell Is on the Horizon
15, Mar, 23Two life-altering treatments could soon be available, but questions remain about how accessible and affordable they’ll be.
New Gene Therapy Could Face Uphill Battle
29, Jun, 23Potential FDA approval of BioMarin’s gene therapy for hemophilia would be major win, but uptake could be slow
US regulators inspect Dr Reddy's, other Indian pharma majors
05, Dec, 23The U.S. Food and Drug Administration is inspecting Dr Reddy's (REDY.NS) research and development centre in the southern Indian city of Hyderabad, the pharma company said on Tuesday.
US FDA gives second approval to Eli Lilly's drug for type of blood cancer
03, Dec, 23Eli Lilly (LLY.N) said on Friday the U.S. Food and Drug Administration (FDA) gave a second approval for its drug Jaypirca, which is used to treat a form of blood cancer.